We are live on ! Find out more
FCMV

Foresite Capital Management V Portfolio holdings

AUM $362M
1-Year Est. Return 386.37%
This Fund
S&P 500
This Quarter Est. Return
+23.08%
1 Year Est. Return
+386.37%
3 Year Est. Return
+400.96%
5 Year Est. Return
+449.59%
10 Year Est. Return
–
AUM
$362M
AUM Growth
+$91.2M
Cap. Flow
+$30.8M
Cap. Flow %
8.51%
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
2
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
PHVS icon
Pharvaris
PHVS
+$14.2M
2
ODTX
Odyssey Therapeutics
ODTX
+$12.5M
3
CGON icon
CG Oncology
CGON
+$4.9M

Top Sells

Rank Stock Value
1
MAZE
Maze Therapeutics
MAZE
+$773K
2
LYEL icon
Lyell Immunopharma
LYEL
+$12.5K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALMS
1
Alumis Inc
ALMS
$1.43B
$166M 45.81%
5,896,995
– –
CGON icon
2
CG Oncology
CGON
$6.6B
$76.7M 21.17%
1,079,050
+75,000
+7% +$4.9M
IRON icon
3
Disc Medicine
IRON
$3.07B
$27.4M 7.55%
374,069
– –
HIMS icon
4
Hims & Hers Health
HIMS
$6.41B
$25.6M 7.07%
738,151
– –
PHVS icon
5
Pharvaris
PHVS
$2.54B
$23M 6.34%
664,142
+470,017
+242% +$14.2M
EIKN
6
Eikon Therapeutics
EIKN
$593M
$17.2M 4.75%
1,318,983
– –
ODTX
7
Odyssey Therapeutics
ODTX
$1.33B
$13.3M 3.68%
+713,105
New +$12.5M
LYEL icon
8
Lyell Immunopharma
LYEL
$351M
$6.69M 1.85%
476,386
-692
-0.1% -$12.5K
NRIX icon
9
Nurix Therapeutics
NRIX
$2.68B
$6.43M 1.77%
265,000
– –
MAZE
10
Maze Therapeutics
MAZE
$1.46B
– –
-25,905
Closed -$773K

Similar funds

AW
Alteri Wealth Westlake Village, California $362M AUM 47.63% 1-Year Est. Return
WMA
Wealth Management Associates Cherry Hill, New Jersey $362M AUM 33.28% 1-Year Est. Return
SI
Saxon Interests Houston, Texas $362M AUM 28.96% 1-Year Est. Return
OBGC
O'Brien Greene & Co Media, Pennsylvania $362M AUM 29.47% 1-Year Est. Return
HA
Hamel Associates Chatham, New Jersey $363M AUM 24.39% 1-Year Est. Return
WIA
Westbourne Investment Advisors Annapolis, Maryland $363M AUM 19.48% 1-Year Est. Return
UFAC
Urban Financial Advisory Corp Chicago, Illinois $363M AUM 17.48% 1-Year Est. Return
FPM
Francisco Partners Management San Francisco, California $361M AUM 30.56% 1-Year Est. Return

Foresite Capital Management V's Q2 2026 Portfolio in Review

As of Q2 2026, Foresite Capital Management V held 10 positions worth $362M, up 34% from $271M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management V deployed $30.8M of net new capital in Q2 2026, opening 1 new position and adding to 2 existing holdings. Its largest new stake was Odyssey Therapeutics: 713,105 shares worth $13.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Lyell Immunopharma, an estimated $12.5K trimmed.

  • Foresite Capital Management V's largest Q2 2026 buy was Odyssey Therapeutics: 713,105 shares worth $13.3M.
  • Foresite Capital Management V added most to Pharvaris in Q2 2026, an estimated $14.2M increase.
  • Foresite Capital Management V's biggest Q2 2026 reduction was Lyell Immunopharma, cutting an estimated $12.5K.
  • Foresite Capital Management V fully exited Maze Therapeutics in Q2 2026, selling an estimated $773K.
  • Foresite Capital Management V's ten largest holdings make up 100% of its $362M portfolio in Q2 2026.
  • Foresite Capital Management V opened 1 new position and closed 1 in Q2 2026.
  • Foresite Capital Management V's portfolio value rose 34% quarter-over-quarter to $362M.

Based on Foresite Capital Management V's 13F filing for Q2 2026, filed 14 Aug 2026.